Monitor the offering's pricing and completion. The company's ability to regain Nasdaq compliance (MVLS >$50M for 10 consecutive days by Jan 11, 2027) is critical — failure could lead to delisting and further liquidity impairment. Watch for clinical data readouts from the oral elraglusib Phase 1/2 study and any partnership/non-dilutive funding for pediatric indications.
Executive Summary
Actuate Therapeutics, a clinical-stage biopharmaceutical company developing elraglusib (a GSK-3 inhibitor for difficult-to-treat cancers), filed an S-1 registration statement for a firm-commitment IPO of 50,000,000 shares of common stock at an assumed price of $0.819 per share (the last reported sale price on October 2, 2026). The company has a going concern qualification, only $4.4M cash as of June 30, 2026, and is not in compliance with Nasdaq's $50M minimum MVLS requirement, making this a dilutive, high-risk capital raise to fund operations and clinical development.
Key Facts
- Offering 50,000,000 shares (57,500,000 if over-allotment exercised) at $0.819/share, raising ~$38.8M net proceeds.
- Cash and cash equivalents of $4,425,841 and working capital of $942,745 as of June 30, 2026.
- Going concern qualification — substantial doubt about ability to continue as a going concern.
- Not in compliance with Nasdaq Global Market $50M minimum MVLS requirement; received deficiency notice on July 15, 2026.
- No revenue from product sales; significant operating losses since inception.
- Underwriter's warrants for 3.5% of shares sold at 125% of IPO price; Bios/Kairos entities receive warrants for 3.7M shares at 150% of IPO price in exchange for 2-year lock-up.
- Phase 2 mPDAC study met primary endpoint (mOS 10.1 vs 7.2 months, HR=0.62, p=0.02).
- Post-offering shares outstanding: 74,013,577 (81,513,577 with over-allotment), up from 24,013,577 — massive dilution of ~208%.
- Net tangible book value per share increases from $0.04 to $0.52, but new investors face $0.30/share immediate dilution.
- Company has $98.7M remaining capacity under ATM facility and 3,364,407 shares available under Committed Equity Facility.
Financial Impact
Net proceeds of approximately $38.8 million from the offering, providing approximately 8-9 months of runway at current burn rate (based on $4.4M cash and $0.94M working capital as of June 30, 2026).
Risk Factors
- Massive dilution of ~208% from 24M to 74M shares outstanding post-offering.
- Going concern risk — only $4.4M cash and negative working capital; proceeds may only fund ~8-9 months.
- Nasdaq delisting risk — not compliant with $50M MVLS requirement; compliance deadline January 11, 2027.
- Pre-revenue clinical-stage company with no approved products and significant operating losses.
- Additional overhang from 3.4M shares available under Committed Equity Facility and $98.7M ATM facility.
- Warrant dilution from underwriter (1.75M shares) and Bios/Kairos (3.7M shares) at exercise prices tied to offering price.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001683168-26-007661 |
| Document: actuate_s1.htm | 0001683168-26-007661 |
| Document: actuate_ex0407.htm | 0001683168-26-007661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.5280 (+11.85%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.5280 (−21.60%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.5280 (+27.07%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.5280 (+45.56%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.5280 (−73.73%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.5280 (−81.73%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.5280 (−74.62%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.5280 (−82.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers